Box of 7 transdermal patches used with the PassPort (TM) Applicator device for the delivery of basal insulin, made by Altea Therapeutics, US, c.2007. The insulin skin patch system is designed to improve and sustain levels of basal insulin to lower the risk of hypoglycemia, as well as ensure greater patient compliance than injecting insulin equivalents and also has the advantage of being stored at room temperature. The Applicator and transdermal patches are non-working models of the technology and do not contain insulin.
The insulin skin patch system is designed to maintain levels of basal insulin – background insulin – in the body. The device called the ‘Applicator’ is used to place a patch to the skin. Once applied, the patch is activated and starts delivering insulin. Applying insulin patches is believed to be more convenient than conventional injections, so it is hoped that people with diabetes will find it easier to maintain their insulin levels using this system.
The device lowers the risk of hypoglycaemia, which occurs when blood sugars are low due to an overdose of insulin, as the patch can be removed immediately. Insulin has to be stored in a refrigerator but the patches can be stored at room temperature. The product was developed by Altea Therapeutics.
- Object Number:
- insulin delivery device
- furnishing and equipment
- tools & equipment
- medical instrument
- drug delivery device
- hypodermic syringe
- Altea Therapeutics
Cite this page
We encourage the use and reuse of our collection data.
Data in the title, made, maker and details fields are released under Creative Commons Zero
Descriptions and all other text content are licensed under a Creative Commons Attribution 4.0 licence
Download catalogue entry as json
View manifest in IIIF viewer
Download manifest IIIF
Our records are constantly being enhanced and improved, but please note that we cannot guarantee the accuracy of any information shown on this website.